Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc

$ 0.75 -0.0081 (-1.07%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 129.78M
Enterprise V:
$ 90.92M
Volume:
690.86K
Avg Vol (2M):
1.75M
Also Trade In:
Volume:
690.86K
Market Cap $:
129.78M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.75M
Enterprise Value $:
90.92M
PB Ratio:
0
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Name Current Vs Industry Vs History
Cash-To-Debt 1.91
Equity-to-Asset -0.17
Debt-to-Equity -2.16
Debt-to-EBITDA -0.55
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -17
Distress
Grey
Safe
Beneish M-Score -3.18
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 43.92
9-Day RSI 45.59
14-Day RSI 42.09
6-1 Month Momentum % -59.81
12-1 Month Momentum % -74.26

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.34
Quick Ratio 2.19
Cash Ratio 1.73
Days Inventory 1300.78
Days Sales Outstanding 64.06
Days Payable 633.22

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.9

Financials (Next Earnings Date:2023-03-01 Est.)

RIGL's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:RIGL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 89.373
EPS (TTM) ($) -0.48
Beta 1.22
Volatility % 67.31
14-Day RSI 42.09
14-Day ATR ($) 0.063319
20-Day SMA ($) 0.743485
12-1 Month Momentum % -74.26
52-Week Range ($) 0.64 - 3.515
Shares Outstanding (Mil) 172.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Rigel Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Rigel Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.